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Objective 1 
Osteoarthritis (OA) associated single nucleotide polymorphism (SNP) rs11780978 correlates 2 
with differential expression of PLEC, and methylation quantitative trait loci (mQTLs) at 3 
PLEC CpGs in cartilage. This implies that methylation links chondrocyte genotype and 4 
phenotype, thus driving the functional effect. PLEC encodes plectin, a cytoskeletal protein 5 
that enables tissues to respond to mechanical forces. We sought to assess whether PLEC 6 
functional effects were cartilage specific. 7 
 8 
Method 9 
Cartilage, fat pad, synovium and peripheral blood were collected from patients undergoing 10 
arthroplasty. PLEC CpGs were analysed for mQTLs and allelic expression imbalance (AEI) 11 
was performed. We focussed on previously reported mQTL clusters neighbouring 12 
cg19405177 and cg14598846. Plectin was knocked down in a mesenchymal stem cell (MSC) 13 
line using CRISPR/Cas9 and cells phenotyped by RNA-sequencing. 14 
 15 
Results  16 
Novel mQTLs were discovered in fat pad, synovium and peripheral blood at both clusters. 17 
The genotype-methylation effect of rs11780978 was stronger in cg14598846 than in 18 
cg19405177 and stronger in joint tissues than in peripheral blood. We observed AEI in 19 
synovium in the same direction as for cartilage. Knocking-down plectin impacted on 20 
pathways reported to have a role in OA, including Wnt signalling, glycosaminoglycan 21 
biosynthesis and immune regulation.  22 
 23 
Conclusions  24 
Synovium is also a target of the rs11780978 OA association functionally operating on PLEC. 25 
In fat pad, mQTLs were identified but these did not correlate with PLEC expression, 26 
suggesting the functional effect is not joint-wide. Our study highlights interplay between 27 
genetic risk, DNA methylation and gene expression in OA, and reveals clear differences 28 
between tissues from the same diseased joint. 29 
 30 
Keywords: osteoarthritis, genetic risk, epigenetics, gene expression, PLEC, CRISPR/Cas9, 31 
cytoskeletal 32 
 33 
 3
Introduction 34 
Osteoarthritis (OA) is an extremely common musculoskeletal disorder that is characterised by 35 
focal loss of articular cartilage leading to chronic pain, disability, co-morbidities including 36 
cardiovascular disease, and premature death1-3. OA is polygenic and in recent years over 90 37 
genome-wide significant loci have been mapped in Europeans using high-density single 38 
nucleotide polymorphism (SNP) arrays4-10. An overwhelming majority of the associated 39 
polymorphisms reside in non-protein-coding regions of the genome and, as such, OA genetic 40 
susceptibility is presumed to act principally via changes to gene expression. The availability 41 
of excised tissue following arthroplasty of an OA joint offers the opportunity to 42 
experimentally test this in disease-relevant cells, including cartilage chondrocytes, the single 43 
cell type in this tissue11. As such, many OA risk alleles have been shown to correlate with 44 
alteration in the expression of nearby genes in chondrocytes12. These effects are known as 45 
expression quantitative trait loci (eQTLs). DNA methylation changes at CG dinucleotides 46 
(CpGs) also regulate gene expression and OA-associated SNPs have been shown to correlate 47 
with methylation levels in cartilage DNA in cis13. These effects are known as methylation 48 
QTLs (mQTLs). Furthermore, several OA risk loci correlate with both methylation and 49 
expression, with alteration of the former being shown experimentally to modulate the latter14. 50 
These effects are known as methylation and expression QTLs (meQTLs). Overall, these 51 
studies indicate that DNA methylation links chondrocyte genotype and phenotype, with this 52 
epigenetic mechanism underpinning and driving a large proportion of the functional impact 53 
of OA genetic risk. Furthermore, in most instances, OA mQTLs localize to predicted 54 
enhancers13, placing OA in the “enhanceropathy” category of common diseases15. 55 
 We previously reported that an OA association marked by SNP rs11780978 (G>A) 56 
correlated with methylation of nine CpGs measured using the Illumina Infinium 57 
HumanMethylation450 genome-wide CpG array16. The SNP and CpGs are all located within 58 
the PLEC gene on chromosome 8q24.3. We subsequently focused on two of the most 59 
significant CpGs from amongst the nine, cg19405177 and cg14598846, and by using 60 
pyrosequencing, we replicated the correlation between rs11780978 genotype and CpG 61 
methylation in an independent panel of DNAs. The two pyrosequencing assays used to 62 
replicate cg19405177 and cg14598846 captured an additional seven CpGs flanking 63 
cg19405177 and an additional three CpGs adjacent to cg14598846. The methylation of these 64 
additional CpGs also correlated with rs11780978 genotype. Furthermore, using allelic 65 
expression imbalance (AEI) analysis (a complementary approach to standard eQTL 66 
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analysis17) we demonstrated that the OA risk-conferring A allele of rs11780978 correlated 67 
with reduced PLEC expression, and that expression of the gene also correlated with 68 
methylation at CpGs in the cg19405177 and cg14598846 clusters16. These mQTL, eQTL and 69 
meQTL studies were all performed on cartilage DNA and RNA, and highlighted PLEC as a 70 
target of the OA susceptibility mapping to chromosome 8q24.3. 71 
PLEC encodes plectin, a large cytoskeletal protein that regulates signalling from the 72 
extracellular environment to the cell nucleus18-19. Plectin enables cells to respond to external 73 
mechanical stimuli and forces, such as those experienced by the chondrocyte during joint 74 
movement20. Although cartilage loss is central to the OA disease process, there are 75 
pathological changes to other tissues of the articulating joint that occur concurrent to and 76 
following the loss of cartilage21. PLEC is expressed widely and in this report, we set out to 77 
test whether the mQTL, eQTL and meQTL effects that we had discovered were cartilage 78 
specific or whether they were active in other joint or non-joint tissues. We also modelled the 79 
transcriptional effect that the OA risk-conferring allele of rs11780978 has on PLEC by 80 
knocking-down plectin in a mesenchymal stem cell line using CRISPR/Cas9 and assessing 81 
the impact on global gene expression. 82 
 83 
Materials and Methods 84 
OA Patients 85 
Tissue samples were collected from patients undergoing knee or hip arthroplasty for primary 86 
OA at the Newcastle upon Tyne Foundation Trust hospitals. Ethical approval was granted by 87 
the Health Research Authority of the National Health Service (research ethics committee 88 
reference 14/NE/1212) and each donor provided verbal and written informed consent. We 89 
collected macroscopically intact cartilage (36 samples, distal from the lesion and avoiding 90 
areas of fibrillated tissue), infrapatellar fat pad (68 samples) and synovium (81 samples). We 91 
also collected whole peripheral blood samples from 55 of the patients just prior to their 92 
surgery, using EDTA vacutainers for DNA extraction and TempusTM tubes for RNA 93 
extraction (ThermoFisher Scientific). In total, we analysed 240 samples from 202 OA 94 
patients, with some patients donating more than one tissue type for analysis. Further patient 95 
details can be found in Supplementary Table 1. 96 
 97 
 98 
 99 
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Nucleic acid extraction from tissue samples 100 
Joint tissue samples were stored frozen and ground to a powder using a mixermill (Retsch 101 
Limited) under liquid nitrogen. For cartilage, RNA was extracted using TRIzol (Life 102 
Technologies) and DNA was extracted using the E.Z.N.A. Tissue DNA isolation kit (Omega 103 
Biotek, VWR). For fat pad and synovium, DNA and RNA were extracted using the E.Z.N.A. 104 
DNA/RNA isolation kit (Omega Biotek, VWR). For blood, DNA was extracted using the 105 
QIAamp DNA blood mini kit (Qiagen) and RNA was extracted using the TempusTM Spin 106 
RNA isolation kit (ThermoFisher Scientific). 107 
 108 
Quantitative gene expression 109 
cDNA synthesis and quantitative PCR (qPCR) were performed as described previously22. 110 
Predesigned TaqMan assays (Integrated DNA Technologies) were used to quantify 111 
expression of the housekeeping genes HPRT1, 18S and GAPDH. For PLEC, expression 112 
primers were designed using the Roche probe library system and are located in exons 19 and 113 
20, which are present in all isoforms of the gene (primers 5'-CTGCGTAGGAAATACAGTT-114 
3' and 5'-CAGCTGTTCCTTCTCGTCCT-3'). The relative expression of PLEC was 115 
calculated by the 2-ΔCt method, where ΔCt is the mean Ct value of the three housekeeping 116 
genes subtracted from the Ct value of PLEC. 117 
 118 
mQTL and eQTL analysis 119 
Genotyping of association SNP rs11780978 and PLEC transcript SNP rs11783799 (A>G), 120 
DNA methylation analysis at the cg19405177 and cg14598846 CpG clusters, and PLEC AEI 121 
analysis using rs11783799 were all performed as described previously using the same 122 
protocols and assays16. For quality control (QC) in the methylation analysis, PCRs were 123 
performed in duplicate on each sample and the mean calculated, with samples being excluded 124 
from the analysis if the methylation between the PCR replicates differed by >5%. For QC in 125 
the AEI analysis, PCRs were performed in triplicate on each tissue cDNA and DNA sample, 126 
with samples excluded from the analysis if the values between the PCR replicates differed by 127 
>5%. Not all samples passed QC for all analyses, which resulted in variable numbers of data 128 
points between assays. Based on our previous investigation of the rs11780978 locus in 129 
cartilage16, we estimated that if the effect sizes were comparable in other tissues, mQTLs and 130 
eQTLs would be detectable at >35 and >15 patient samples respectively. 131 
 132 
 133 
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Generation of a mesenchymal stem cell line constitutively expressing Cas9 (MSC-Cas9) 134 
We purchased the immortalised human mesenchymal stem cell (MSC) line SCRC-4000 135 
(ATCC) and transduced it with the lentiCRISPR v2 plasmid 52961, which contains a Cas9 136 
insert and confers puromycin resistance (Addgene). The cells were expanded in complete 137 
growth medium consisting of serum free media (PCS-500-030, ATCC) supplemented with 138 
Mesenchymal Stem Cell Growth Kit containing L-Alanyl-L-Glutamine (PCS-500-040, 139 
ATCC), G418 disulphate salt solution (G8168, Sigma Aldrich) and penicillin-streptomycin 140 
(30-2300, ATCC). Selection of Cas9 expressing cells was achieved by addition of 0.35ug/µl 141 
of puromycin to the complete growth media. Constitutive expression of Cas9 was confirmed 142 
by immunoblot with a Cas9 antibody (7A9-3A3, Cell Signalling Technology). 143 
 144 
CRISPR/Cas9 145 
CHOPCHOP (https://chopchop.cbu.uib.no/) was used to design guide RNA (gRNA) 146 
sequences that would generate a 26bp frame-shift deletion of exon 3 of PLEC (primers 5'-147 
CTGTATGAAGACCTCCGCGA-3' and 5'-CCCCGAGAGGACCTCCAGCA-3'). This exon 148 
is present in all isoforms of the gene. The gRNAs were then purchased as synthetic Alt-R® 149 
CRISPR-Cas9 crRNAs alongside Alt-R® CRISPR-Cas9 tracrRNA (Integrated DNA 150 
Technologies). MSC-Cas9 cells were plated at sub-confluence (45,000 cells/well) in 6-well 151 
plates (VWR) and allowed to adhere for 24 hours. For deletions (4 replicates), paired crRNAs 152 
were annealed to tracrRNA in a 1:1:2 ratio at 95oC for 5 minutes, whilst for controls (4 153 
replicates), tracrRNA alone was used. Deletion and control mixes were separately combined 154 
with Dharmafect1 (Dharmacon) in serum free media (PCS-500-030, ATCC) to produce a 155 
transfection mix. 200ul of media/well was aspirated and replaced with transfection mix for 24 156 
hours, after which the media was changed to complete growth medium and the cells 157 
expanded in T182.5 flasks (VWR) in monolayer and until confluent (between 10-14 days), 158 
with two changes of media per week. Cells were detached by trypsinization, washed in 159 
phosphate-buffered saline (PBS), spun and the cell pellets frozen. DNA, RNA and protein 160 
were simultaneously extracted from pellets using the NucleoSpin TriPrep Kit (Macherey-161 
Nagel, supplied by ThermoFisher). Deletion of the target region was confirmed by end-point 162 
PCR of DNA using primers flanking the guides (primers 5'-163 
GAGGGGTTGAGCTGGATTCC-3' and 5'-CCAGCACCCACTCTGTAGAT-3') and by 164 
Sanger sequencing. 165 
 166 
 7
 167 
Immunoblotting 168 
Up to 10µg of total protein was resolved on NuPAGE™ 3-8% Tris-Acetate Protein Gels 169 
(Invitrogen) in 1x NuPAGE™ Tris-Acetate SDS Running Buffer (Invitrogen). Protein was 170 
transferred through a semi-dry transfer at 200mA/gel for 3 hours. Blots were probed with 171 
anti-plectin guinea pig polyclonal serum (GP21, Progen)/goat anti-guinea pig (AB6908, 172 
Abcam) and anti-GAPDH (MAB374, Sigma Aldrich)/goat anti-mouse (P0447, Dako) as a 173 
loading control. 174 
 175 
RNA-sequencing 176 
For each sample, the TruSeq Stranded mRNA library prep kit (Illumina) was used to prepare 177 
a sequencing library from 1.5µg of total RNA. All samples were then sequenced to a depth of 178 
~52-71 million paired end reads on an Illumina NextSeq platform. QC of raw sequencing 179 
reads was performed using FastQC (v0.11.7). All samples passed QC. Reads were mapped to 180 
the hg38 (ENSEMBL version 91) reference genome using Salmon (v0.14.1) in quasi-181 
mapping mode on default settings23. All samples except one achieved alignment rates of 182 
~88%. Counts were summarised to gene level and imported into R using tximport24. Principle 183 
component analysis (PCA) revealed the sample with the low alignment rate to be an outlier 184 
and this was removed from further analysis, leaving four PLEC deletion and three controls. 185 
Unwanted variation in the dataset was estimated using surrogate variable analysis (svaseq25). 186 
The number of surrogate variables was estimated at two and these were included into the 187 
model for differential expression analysis. Differential expression analysis between deletion 188 
and control samples was performed using the Wald test implemented in DESeq226. The false 189 
discovery rate (FDR) was controlled using the Benjamini-Hochberg procedure. Genes with 190 
an FDR P<0.05 were considered significant. Gene set enrichment analysis (GSEA27) was 191 
used to discover overrepresented pathways in the set of up- and down-regulated genes. The 192 
full gene list was ranked by signed log10(P value); positive sign if up-regulated and negative 193 
if down-regulated. This pre-ranked list was used as input into the fgsea package in 194 
Bioconductor to query enrichment of Reactome pathways28. Pathways with an FDR P<0.25 195 
were considered significant, as recommended by the developers of GSEA27. To visualise 196 
splice junctions, reads were aligned to hg38 reference genome using STAR (v2.4.2a) short 197 
read aligner using default settings29 and viewed in Integrative Genomics Viewer (IGV30). 198 
 199 
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 200 
Statistical analyses 201 
When correlating association between rs11780978 genotype and methylation of CpGs, P 202 
values were calculated using the Kruskal-Wallis test. For comparison of global methylation 203 
between tissues, Kruskal-Wallis with Dunn’s multiple comparisons was used. For 204 
quantitative PLEC expression analyses, P values were calculated using a Mann-Whitney 2-205 
tailed exact test. For PLEC AEI, P values were calculated using Wilcoxon’s matched pairs 206 
signed rank test. For heat maps, the correlation between all three genotypes (GG, GA and 207 
AA) and methylation was determined using adjusted r2 values calculated using a standard 208 
least squares linear regression model and expressed as a percentage. 209 
 210 
Results 211 
PLEC cartilage mQTLs are present in other tissues 212 
We previously discovered PLEC mQTLs in cartilage DNA16. For cg19405177 and its seven 213 
flanking CpGs (located in a 124bp interval), the OA risk-conferring A allele of rs11780978 214 
correlated with increased methylation, whereas for cg14598846 and its three adjacent CpGs 215 
(located in a 21bp interval), the A allele correlated with decreased methylation. 216 
Supplementary Figure 1 highlights the relative positions of rs11780978 and the CpGs in 217 
PLEC. In this report, we first assessed if these mQTLs were also active in DNA from fat pad, 218 
synovium and blood. We also included a new cohort of cartilage DNAs. Figure 1 provides 219 
the data for cg19405177 and cg14598846, whilst the data for all 12 CpGs across the four 220 
tissues can be found in Supplementary Figures 2 (cartilage), 3 (fat pad), 4 (synovium) and 5 221 
(blood). The mQTLs were replicated in the new batch of cartilage DNAs and in the same 222 
directions as before. The mQTLs were also present in the other tissues and also in the same 223 
direction.  224 
When we plotted the methylation data by tissue type but independent of genotype, 225 
there were significant differences in methylation levels (Supplementary Figure 6). For 226 
example, cg19405177 demonstrated higher methylation values in fat pad and synovium 227 
compared to cartilage and blood, whilst cg14598846 demonstrated higher methylation values 228 
in blood compared to joint tissues. To emphasize this variability in CpG methylation in 229 
tissues from the same patient, we plotted the cg19405177 and cg14598846 data for those 230 
patients in whom we had studied two or more tissues. There were 18 such patients with data 231 
generated at cg19405177 and 20 patients with data generated at cg14598846 (Figure 2). The 232 
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variability in methylation between the tissues of an individual is particularly clear for patient 233 
6550 at cg19405177, and patient 6599 at cg14598846, with a methylation range of >30% 234 
across the four tissues tested for each CpG. 235 
We next constructed heat maps of the percentage effect of rs11780978 genotype on 236 
methylation at each CpG in each tissue. For cartilage, we included data from the replication 237 
study of our previous report16 to maximise power. For the cg19405177 CpGs, the average 238 
genotypic effect for all eight CpGs combined was 31.3% in cartilage, 17.4% in fat pad, 21.2 239 
% in synovium and 9.3% in blood (Figure 3A). For the cg14598846 CpGs, the average 240 
genotypic effect for all four CpGs combined were comparable across the joint tissues, with 241 
values of 85.0% in cartilage, 81.4% in fat pad and 87.5% in synovium (Figure 3B). Although 242 
the genotypic effect in blood was lower, it was still high at 43.5%. At the individual CpG 243 
level, there were some striking differences between tissues. For example, cg19405177 had a 244 
genotypic effect of >30% in cartilage, synovium and blood but only 3.9% in fat pad. These 245 
large differences imply intra-tissue differences in the nature of the mQTLs. 246 
Overall, this analysis highlighted that the previously reported PLEC mQTLs are 247 
active in non-cartilaginous tissues and that the effects are stronger in joint tissues than blood. 248 
Although the genotypic effect of rs11780978 is greater in cartilage for the cg19405177 CpGs, 249 
this is not the case for the cg14598846 CpGs.  250 
 251 
The PLEC rs11780978 eQTL is active in synovium 252 
Before testing for the PLEC rs11780978 eQTL by AEI analysis, we measured the relative 253 
expression of the gene in fat pad, synovium and blood along with cartilage as a comparator 254 
(Supplementary Figure 7). The qPCR data revealed that PLEC expression was equivalent 255 
between cartilage and synovium, was higher in fat pad and lower in blood. 256 
We performed AEI as described previously16. In summary, we identified rs11780978 257 
heterozygotes who were also heterozygous for the PLEC transcript SNP rs11783799 258 
(r2=0.93; the OA risk conferring A allele of rs11780978 correlates with the G allele of 259 
rs11783799). We then used rs11783799 to quantify the relative allelic expression of PLEC in 260 
the compound heterozygotes. The blood cDNA samples consistently failed QC, with the PCR 261 
replicates differing by >5% in all samples. This is likely a reflection of the lower expression 262 
of PLEC in this tissue and we could not therefore generate blood AEI data. We were able to 263 
generate AEI data for 19 fat pad and 20 synovium compound heterozygotes (Figure 4). AEI 264 
was detectable in both tissues and as for our previous study in cartilage16, the AEI ratios 265 
varied between patients, implying that other genetic polymorphisms can also modulate PLEC 266 
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expression. Only in synovium did the direction of AEI significantly correlate with an allele of 267 
rs11783799, with reduced expression of PLEC correlating with the G allele of the SNP in the 268 
combined analysis (P=0.0054; Figure 4B). In fat pad, AEI was observed in a majority of the 269 
patients, but this did not correlate with a particular allele (P=0.31; Figure 4A).  270 
To emphasize the variability of AEI in tissues from the same patient, we next plotted 271 
the data for those patients in whom we had studied fat pad and synovium (Supplementary 272 
Figure 8). There were six such patients with clear variability in the G/A ratio between the two 273 
tissues tested for most of these, with patients 5680 and 5725 demonstrating particularly clear 274 
inter-tissue variability in the ratio; in both, the G allele is more highly expressed in fat pad 275 
but more lowly expressed in synovium relative to the A allele. 276 
The significant AEI in synovium was in the same direction that we had observed in 277 
cartilage16, with the G allele of rs11783799, which marks the OA risk conferring A allele of 278 
rs11780978, demonstrating reduced PLEC expression. In that previous report, we had studied 279 
19 cartilage compound heterozygotes and the mean G/A ratio was 0.89. The mean synovium 280 
G/A ratio we detected here was 0.92. 281 
We next plotted the PLEC AEI data for the fat pad and synovium compound 282 
heterozygotes against their individual methylation data. In fat pad, there was no evidence of a 283 
significant correlation between methylation and AEI at cg19405177, cg14598846 or the 284 
additional 10 CpGs measured (all P values >0.05; Supplementary Figure 9). However, in 285 
synovium, three of the CpGs correlated with AEI; CpG3 from the cg19405177 cluster 286 
(P=0.049), and cg14598846 (P=0.039) and CpG2 (P=0.047) from the cg14598846 cluster 287 
(Supplementary Figure 10). These three CpGs had also shown meQTL activity in our 288 
previous cartilage study16. For CpG3 from the cg19405177 cluster, the same direction of 289 
effect is seen in cartilage and synovium, with increased methylation correlating with 290 
decreased AEI (the log2 AEI ratio moves towards zero with increasing methylation). 291 
However, for cg14598846 and CpG2 from the cg14598846 cluster, the effects are in opposite 292 
directions between cartilage and synovium; in cartilage, increased methylation correlated 293 
with decreased AEI whereas in synovium, increased methylation correlated with increased 294 
AEI (the log2 AEI ratio moves away from zero with increasing methylation).  295 
In summary, the PLEC rs11780978 eQTL previously observed in cartilage also 296 
operates in synovium. Furthermore, we observed correlations between PLEC expression and 297 
CpG methylation in synovium. These meQTLs are shared with cartilage but are not 298 
necessarily operating in the same manner. 299 
 300 
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 301 
Knock-down of PLEC and plectin elicits a response 302 
Our previous data and the results generated here highlight that the OA risk conferring A 303 
allele of rs11780978 correlates with decreased expression of PLEC in cartilage and 304 
synovium. We modelled this effect by knocking-down plectin in an immortalised human 305 
MSC cell line. We chose to use this line because: 1) being an MSC line, it is biologically 306 
relevant to joint cells; 2) it expressed PLEC at a high level and; 3) it is readily transfectable 307 
and modifiable via CRISPR/Cas931. We transduced it to constitutively express Cas9 and we 308 
then generated a 26bp frame-shift deletion of PLEC exon 3, with four replicates for deletion 309 
and four control replicates. The cells were cultured in monolayer for up to 14 days and the 310 
deletion was confirmed by PCR and Sanger sequencing, whilst a near-total plectin knock-out 311 
was observed by immunoblotting using an antibody that binds to the C-terminus of the 312 
protein (Figure 5A-C). The isolated RNA was then subjected to next-generation mRNA 313 
sequencing. This revealed alternate splicing occurring in PLEC in the deletion samples, with 314 
exon 3 being completely skipped in a subset of transcripts (Figure 5D). No exon skipping 315 
was seen in the control samples. The level of PLEC mRNA was 26% lower in the deletion 316 
samples compared to the controls (log2 fold change of -0.44; FDR P=0.001; Supplementary 317 
Table 2). In summary, this data implies that the Cas9-mediated deletion impacted on the 318 
transcription of PLEC and on the translation of PLEC mRNA into plectin. 319 
 We next assessed the effect of this plectin knock-down on the transcriptome. In 320 
addition to PLEC, the deletion had a significant effect (FDR P<0.05) on the expression of 321 
269 genes (Figure 6A and B, Supplementary Table 2). Pathway analysis revealed increased 322 
expression of genes related to processes involving immune regulation and protein post-323 
translation modification (Figure 6C), and decreased expression of genes related to Wnt 324 
signalling, metabolic pathways and glycosaminoglycan biosynthesis, amongst others (Figure 325 
6D). In conclusion, this model system highlighted that depletion of PLEC and plectin 326 
impacted upon a range of pathways reported to play a critical role in cartilage biology and 327 
OA. 328 
 329 
Discussion 330 
The mapping of risk loci for polygenic traits is now a relatively straightforward procedure, 331 
with the next major step in complex trait analysis being the transition from association signal 332 
to functional characterization32. For OA, considerable strides have been made in this regard 333 
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in recent years33-35. Our interest is in the epigenetic dimension of OA genetic risk and 334 
especially the role of DNA methylation. This is the best characterized and most stable 335 
epigenetic modification and modulates gene expression by disrupting the binding of 336 
transcription factors and by facilitating the binding of methyl-binding proteins, which initiate 337 
compaction of chromatin and gene silencing36. Last year, we demonstrated that the OA 338 
association signal marked by SNP rs11780978 correlated with methylation of CpGs within 339 
PLEC and with variable expression of the gene16. These analyses were chondro-centric and 340 
here, we set out to determine whether these functional effects were more widespread. If so, 341 
an exclusive focus on cartilage as a target tissue of the rs11780978 association signal would 342 
not be merited.  343 
 We discovered that the rs11780978-PLEC eQTLs, mQTLs and meQTLs that are 344 
active in cartilage are also active in synovium, but with some differences; the genotypic 345 
effect is substantially greater in cartilage for the cg19405177 cluster of CpGs, whilst the 346 
cg14598846 meQTLs act in opposite directions between the two tissues. Further 347 
investigation in additional cohorts should confirm whether both the commonalty and discord 348 
of the effects that we have observed between cartilage and synovium are robust. In fat pad, 349 
we observed the mQTLs but PLEC AEI did not correlate with rs11780978 genotype. Instead, 350 
the OA risk-conferring A allele of rs11780978 demonstrated increased and decreased 351 
expression relative to the non-risk allele across the 19 fat pad samples studied, with no 352 
overall significant difference when the data was combined. There are therefore eQTLs 353 
operating on PLEC in fat pad, but these are unrelated to rs11780978. These distinctions point 354 
toward regulatory variability in gene expression mediated by the same association between 355 
joint tissues. In blood, the mQTLs were detectable but their genotypic effect was much 356 
weaker in comparison to the three joint tissues. Such variable strengths of mQTLs effects 357 
between cells from different lineages are expected37. We were unable to test blood for PLEC 358 
eQTLs due to the low expression level of the gene. In summary, we observed the PLEC 359 
mQTLs across all four tissues tested with the joint tissues more similar to each other than to 360 
blood.  This was exemplified by the mQTL genotypic effects being much stronger in joint 361 
tissues. Since synovium was subject to eQTLs and meQTLs, it too should be investigated as a 362 
target of the rs11780978 association signal. 363 
 In our QTL analyses, we did not correct for the number of tests performed as our 364 
study was based on our prior discoveries in cartilage16 and we wanted to avoid overlooking 365 
results where the effect size may be modest. Our QTL results may therefore have an inflated 366 
type I error rate. 367 
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Finally, we modelled the effect of the rs11780978 risk-conferring allele by knocking 368 
down plectin in a cell line. PLEC mRNA was detectable in the RNA-sequencing data but at a 369 
significantly lower level compared to control. The knock-down was very efficient at the 370 
protein level, with a near total absence of plectin observed. The knock-down impacted on a 371 
range of cellular pathways. Of particular note, increased expression of genes involved in 372 
pathways of the innate and the acquired immune response was observed, an effect that has 373 
been reported on previously in OA for both cartilage and synovium38-39. Furthermore, we 374 
observed decreased expression of genes related to Wnt signalling, which was also of interest 375 
as this pathway is critical to cartilage homeostasis33,40 and there is growing evidence of an 376 
interplay between Wnt signalling and inflammation in joint tissues41. Future work would aim 377 
to validate these findings at the protein level, to elucidate pathway directionality in response 378 
to plectin deficiency. 379 
Our model system did not include mechanical load, a force which plectin allows cells 380 
to respond to18-20. Aberrant mechanical load, including only moderate change, can elicit an 381 
inflammatory response that has been termed “mechanoflammation”42. Our data suggests that 382 
even in the absence of load, the loss of plectin is eliciting this response. A future model 383 
incorporating load may therefore reveal yet more insight into a potential key role of plectin as 384 
a regulator of inflammation in response to mechanical load and joint tissue injury in OA. This 385 
model should incorporate plectin deficient differentiated joint cells, rather than the 386 
undifferentiated MSCs investigated here, to more accurately recapitulate the articulating 387 
joint. Furthermore, and despite our inability to undertake PLEC AEI on blood cells, we 388 
should not exclude circulating immune cells as potential targets of the rs11780978 389 
association signal, particularly in light of the altered expression of plectin in macrophages in 390 
response to immunomodulatory agents43.  391 
In conclusion, our investigations have highlighted the interplay between OA genetic 392 
risk, DNA methylation and gene expression, and reveal clear differences in these effects for 393 
tissues from the same diseased joint. Furthermore, by recapitulating the effect of the risk 394 
locus at PLEC, we have linked OA genetic susceptibility with a number of cellular pathways, 395 
thus providing mechanistic insight into OA aetiology.  396 
 397 
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Legends to figures 539 
Figure 1. Association between rs11780978 genotype and methylation at CpGs cg19405177 540 
and cg14598846 in cartilage, fat pad, synovium and blood DNA. P values were calculated 541 
using the Kruskal-Wallis test. Horizontal lines and error bars show the mean ± SEM.  542 
n = the number of patients providing data per CpG site for each tissue. 543 
 544 
Figure 2. Differences in methylation within tissues of the same patient. Methylation at CpGs 545 
cg19405177 (A) and cg14598846 (B) were plotted for those individuals in whom methylation 546 
data was generated for two or more tissues. Numbers on the x-axis refer to the anonymised 547 
identification number assigned to patients at recruitment. Data is grouped by genotype at 548 
rs11780978. 549 
 550 
Figure 3. Heat maps displaying the percentage effect of genotype at rs11780978 upon 551 
methylation at CpG clusters cg19405177 (A) and cg14598846 (B) for the four patient tissues. 552 
Data analysis was performed using SAS JMP Statistical Data Visualization Software and heat 553 
maps produced in PRISM. Patients contributing data to the cg19405177 cluster 1: cartilage, 554 
n=81; fat pad, n=39; synovium, n=64; blood, n=43. Patients contributing data to the 555 
cg14598846 cluster: cartilage, n=103; fat pad, n=68; synovium, n=79; blood, n=54. 556 
 557 
Figure 4. PLEC allelic expression imbalance (AEI) in fat-pad (A) and synovium (B). AEI 558 
analysis was conducted using transcript SNP rs11783799. The risk/non-risk allelic ratio is 559 
plotted, with a ratio <1 indicating decreased PLEC expression from the risk allele. For each 560 
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patient, the mean of the DNA ratio (black, n=3 technical repeats) and the mean of the cDNA 561 
ratio (grey, n=3 technical repeats) is plotted. Numbers on the x-axis refer to the anonymised 562 
identification number assigned to patients at recruitment. The values for DNA and cDNA for 563 
all patients combined are represented as box plots to the right, in which the lines within the 564 
box represent the median, the box represents the 25th to 75th percentile, and the whiskers 565 
represent the maximum and minimum values. P values were calculated using Wilcoxon’s 566 
matched pairs signed rank test. 567 
 568 
Figure 5. Knock-down of plectin using CRISPR/Cas9. (A) The 26bp sequence of PLEC exon 569 
3 deleted. (B) Representative agarose gel image showing the PCR product for control (non-570 
deleted) and deletion. (C) Representative immunoblot comparing plectin levels in control 571 
versus deletion, with GAPDH as a loading control. (D) Sashimi plot showing splicing of 572 
merged PLEC deletion (red) and control (blue) samples. Data were viewed on IGV genome 573 
browser. The multiple isoforms of PLEC are shown on the bottom of the panel. Read 574 
coverages show the presence of reads within exons. The lines illustrate the splicing between 575 
exons. The values on the lines show the number of junction spanning reads. The merged 576 
deletion track shows the absence of the 26bp region deleted within PLEC exon 3 (indicated 577 
by the box). 578 
 579 
Figure 6. Differentially expressed genes and pathways. (A) Volcano plot illustrating 580 
significantly differentially expressed genes between PLEC deletion and control samples. The 581 
x-axis shows the log2 fold change between condition and the y-axis shows the -log10(FDR). 582 
Genes with an FDR P<0.05 are shown in red. (B) Heatmap of significantly differentially 583 
expressed genes between PLEC deletion and control. Normalized counts were used for 584 
plotting. Hierarchical clustering was used to cluster samples and genes. The heatmap shows 585 
that samples cluster by condition (D0-Del, deletions; D0-Neg, controls). (C) Top 25 586 
significantly upregulated Reactome pathways found using GSEA. (D) Top 25 significantly 587 
downregulated Reactome pathways found using GSEA. All genes were ranked using signed 588 
log10(P-value) and this pre-ranked list used as input into GSEA to query enrichment of 589 
Reactome pathways.  590 
 591 
Supplementary Figure 1. The location in PLEC of rs11780978 and the analysed CpGs. The 592 
PLEC gene is shown in blue, exons are boxes/vertical lines, and the direction of transcription 593 
is from right to left. The cg19405177 assay captures a total of 8 CpGs, the cg14598846 assay 594 
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a total of four. cg19405177 and cg14598846 are marked as red circles, the additional CpGs as 595 
black circles. The physical position of the CpGs on chromosome 8 (hg19 assembly, UCSC 596 
Genome Browser) is shown. 597 
 598 
Supplementary Figure 2. Association between rs11780978 genotype and methylation at 599 
CpG clusters cg19405177 (A) and cg14598846 (B) in cartilage DNA. P values were 600 
calculated using the Kruskal-Wallis test. Horizontal lines and error bars show the mean ± 601 
SEM. n = the number of patients providing data per CpG site. 602 
 603 
Supplementary Figure 3. Association between rs11780978 genotype and methylation at 604 
CpG clusters cg19405177 (A) and cg14598846 (B) in fat pad DNA. P values were calculated 605 
using the Kruskal-Wallis test. Horizontal lines and error bars show the mean ± SEM. n = the 606 
number of patients providing data per CpG site. 607 
 608 
Supplementary Figure 4. Association between rs11780978 genotype and methylation at 609 
CpG clusters cg19405177 (A) and cg14598846 (B) in synovium DNA. P values were 610 
calculated using the Kruskal-Wallis test. Horizontal lines and error bars show the mean ± 611 
SEM. n = the number of patients providing data per CpG site. 612 
 613 
Supplementary Figure 5. Association between rs11780978 genotype and methylation at 614 
CpG clusters cg19405177 (A) and cg14598846 (B) in blood DNA. P values were calculated 615 
using the Kruskal-Wallis test. Horizontal lines and error bars show the mean ± SEM. n = the 616 
number of patients providing data per CpG site. 617 
 618 
Supplementary Figure 6. Methylation at CpG clusters cg19405177 (A) and cg14598846 (B) 619 
for the four patient tissues without stratification by rs11780978 genotype. P values were 620 
calculated using Kruskal-Wallis with Dunn’s multiple comparisons. Horizontal lines and 621 
error bars show the mean ± SEM. n = the number of patients providing data per tissue and at 622 
each CpG site. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 ****P ≤ 0.0001. 623 
 624 
Supplementary Figure 7. Expression of PLEC in tissue samples from OA patients. PLEC 625 
mRNA levels were measured by qPCR in cartilage (n=10), fat pad (n=9), synovium (n=10) 626 
and blood (n=10). Horizontal lines and error bars show the mean ± SEM. P values were 627 
calculated using a Mann-Whitney 2-tailed exact test. **P ≤ 0.01; ***P ≤ 0.001 628 
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 629 
Supplementary Figure 8. The six patients with AEI data for fat pad (FP) and synovium 630 
(SYN). The risk/non-risk allelic ratio is plotted, with a ratio <1 indicating decreased PLEC 631 
expression from the risk allele. For each patient, the mean of the DNA ratio (black, n=3 632 
technical repeats) and the mean of the cDNA ratio (grey, n=3 technical repeats) is plotted. 633 
Numbers on the x-axis refer to the anonymised identification number assigned to patients at 634 
recruitment. 635 
 636 
Supplementary Figure 9. Methylation expression quantitative trait locus analyses in fat pad. 637 
PLEC log2 allelic expression imbalance (AEI) ratios were plotted against methylation at all 638 
CpGs in the cg19405177 (A) and cg14598846 (B) clusters. The square of the correlation 639 
coefficient (r2) and P values were calculated by linear regression analysis using a standard 640 
least squares model. 641 
 642 
Supplementary Figure 10. Methylation expression quantitative trait locus analyses in 643 
synovium. PLEC log2 allelic expression imbalance (AEI) ratios were plotted against 644 
methylation at all CpGs in the cg19405177 (A) and cg14598846 (B) clusters. The square of 645 
the correlation coefficient (r2) and P values were calculated by linear regression analysis 646 
using a standard least squares model. 647 
Figure	1
Figure	3
A
B
Figure	2
A B
Figure 4
A
B
DNA
De
le
tio
n
Co
nt
ro
l
5’ CTCCAGCAGGGAGATGAGGTTGTGGCCATCGCGGAG 3’ 
5’ CTCCA                          CGGAG 3’ 
26bp	deletion
Control
Deletion
B
Protein
Plectin
GAPDH
De
le
tio
n
Co
nt
ro
lC
D
A
Exon	3
PLEC
Deletion
Control
Figure	5
010
20
30
40
−1.0 −0.5 0.0 0.5 1.0
log2FoldChange
−l
og
10
(F
DR
)
FDR < 0.05
No
Yes
METABOLISM_OF_WATER_SOLUBLE_VITAMINS_AND_COFACTORS
MET_PROMOTES_CELL_MOTILITY
INTERLEUKIN_10_SIGNALING
CARGO_CONCENTRATION_IN_THE_ER
O_LINKED_GLYCOSYLATION
ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP
DISEASE
ADAPTIVE_IMMUNE_SYSTEM
COMPLEMENT_CASCADE
O_LINKED_GLYCOSYLATION_OF_MUCINS
INTERLEUKIN_20_FAMILY_SIGNALING
INITIAL_TRIGGERING_OF_COMPLEMENT
ANTIGEN_PRESENTATION:_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF
CHOLESTEROL_BIOSYNTHESIS
METABOLISM_OF_STEROIDS
METABOLISM_OF_LIPIDS
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM
INNATE_IMMUNE_SYSTEM
INTERFERON_SIGNALING
INTERFERON_ALPHA_BETA_SIGNALING
INTERFERON_GAMMA_SIGNALING
ASPARAGINE_N_LINKED_GLYCOSYLATION
POST_TRANSLATIONAL_PROTEIN_MODIFICATION
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES
BETA_CATENIN_INDEPENDENT_WNT_SIGNALING
DEGRADATION_OF_DVL
ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS
METABOLISM_OF_RNA
CHONDROITIN_SULFATE_BIOSYNTHESIS
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS
MITOCHONDRIAL_PROTEIN_IMPORT
CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES
SIGNALING_BY_RHO_GTPASES
RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_HSCS
TRANSCRIPTIONAL_REGULATION_BY_RUNX1
COMPLEX_I_BIOGENESIS
MITOCHONDRIAL_TRANSLATION
SUMOYLATION_OF_DNA_METHYLATION_PROTEINS
PCP_CE_PATHWAY
EPHB_MEDIATED_FORWARD_SIGNALING
TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT
RHO_GTPASE_EFFECTORS
RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING
THE_CITRIC_ACID_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT
RESPIRATORY_ELECTRON_TRANSPORT
MRNA_SPLICING
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR
SIGNALING_BY_WNT
REACTOME Pathways
REACTOME Pathways
0.4 0.5 0.6 0.7 0.8 0.9
Enrichment Score
−0.8 −0.7 −0.6 −0.5 −0.4
Enrichment Score
Enrichment
0.4
0.5
0.6
0.7
0.8
0.9
0.12
0.13
0.14
FDR
0.116
0.120
0.124
FDR
Enrichment
−0.7
−0.6
−0.5
−0.4
Upregulated Pathways
Downregulated Pathways
PLEC deletion vs control
METABOLISM_OF_WATER_SOLUBLE_VITAMINS_AND_COFACTORS
MET_PROMOTES_CELL_MOTILITY
INTERLEUKIN_10_SIGNALING
CARGO_CONCENTRATION_IN THE_ R
O_LINKED_GLYCOSYLATION
ACTIVATION_OF_GE E_EXPRESSION_BY_SREBF_SREBP
DISEASE
ADAPTIVE_IMMUNE_SYSTEM
COMPLEMENT_CASCADE
O_LINKED_GLYCO YLATION_OF_MUCINS
INTERLEUKIN_20_FAMILY_ IGNALING
INITIAL_TRIGGERING_OF COMPLEMENT
ANTIGEN_PRESENTATION:_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_ F_CLASS I_MHC
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF
CHOLESTEROL_BIOSYNTHESIS
METABOLISM_OF_STEROIDS
METABOLISM_OF_LIPIDS
CYTOKINE_SIGNALING_IN_I UNE_SYSTEM
IN ATE_IMMUNE_SYSTEM
INTERFERON_SIGN LING
INTERFERON ALPHA_BET _SIGNALING
INTERFERON_GAMMA_SIGNALING
ASPARAGINE_N_LINKED_GLYCOSYLATION
POST_TRANSLATIONAL_PROTEIN_MODIFICATION
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES
BETA_CATENIN_INDEPENDENT_WNT_ IGNALING
DEGRADATION_OF_DVL
ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS
METABOLISM_OF_RNA
CHONDROITI _SULFATE BIOSYNTHESI
ACTIVATION_OF_NF_KAPP B_I B_CELL
MI OCHONDRIAL_PR TEIN_IMPORT
CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIG NS_ENDOSOME
SIGNALI G_BY_RHO_GTPASES
RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INV LVED_IN_DIFF RENTIATION_OF_HSC
TRANSCRIPTIONAL_REGULATION_BY_RUNX1
COMPLEX_I_BIO ENESIS
MITOCHO DRIAL_TRANSLATION
SUMOYLATION_OF_DNA_METHYL TION_PROTEIN
PCP_ E_PATHWAY
EPHB_MEDIATED_FORWARD_SIGNALING
TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WN
RHO_GTPASE_EFFECTORS
RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLI G
THE_CITRIC_ACID_TCA_CYCLE_AND_R SPIRATORY_ELECTRON_TRANSPORT
RESPIRATORY_ELECTRON_TRANSPOR
MRNA_SPLICING
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR
SIGNALING_BY_WNT
REACTOME Pathways
REACTOME Pathways
0.4 0.5 0.6 0.7 0.8 0.9
Enrichment Score
−0.8 −0.7 −0.6 −0.5 −0.4
Enrichment Score
Enrichment
0.4
0.5
0.6
0.7
0.8
0.9
0.12
0.13
0.14
FDR
0.116
0.120
0.124
FDR
Enrichment
−0.7
−0.6
−0.5
−0.4
Upregulated Pathways
Downregulated Pathways
PLEC deletion vs control
Figure	6
A
6−D0−Neg
7−D0−Neg
8−D0−Neg
1−D0−Del
4−D0−Del
2−D0−Del
3−D0−Del
Condition
Control
Deletion
−2
−1
0
1
2
B
C
D
